Cardiovascular Pharmacology

Session · 30 of 35

Cardiovascular pharmacology drives the field forward. Sessions cover GDMT for HFrEF and HFpEF, antithrombotic and anticoagulant strategy (DOACs, factor XI inhibitors), lipid-lowering therapy across the spectrum, antihypertensive combinations including the polypill, antiarrhythmic positioning, and the RNAi and gene-editing pipeline targeting Lp(a), PCSK9, ANGPTL3 and TTR. Discussion includes drug-drug interactions, pharmacogenomics, adherence, biosimilar timelines and the regulatory landscape.

Topics covered in this session

GDMT for HFrEF and HFpEF
Antithrombotic strategy (DOACs, FXI)
Lipid-lowering across the spectrum
Antihypertensive combinations
Antiarrhythmic positioning
RNAi and gene-editing pipeline
Pharmacogenomics
Biosimilars and access

Submit to this session All sessions

Other Sessions

Explore the full GCCM 2027 program

Open the full sessions overview